KCM
RPRX

Kingdon Capital Management’s Repros Therapeutics Inc. RPRX Stock Holding History

Kingdon Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-220,000
Closed -$5.9M – 246
2013
Q3 		$5.9M Buy
+220,000
New +$4.71M 0.29% 106

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
AIA
Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Kingdon Capital Management's RPRX Position: Q3 2014 in Review

Kingdon Capital Management sold out of Repros Therapeutics Inc. (RPRX) in Q3 2014, closing a stake of 92,318 shares — an estimated $1.6M sold.

Kingdon Capital Management first reported a position in RPRX in Q2 2013 and held it in 5 quarters. The position peaked at $13.2M in Q2 2013. 75 funds tracked by Wall St. Rank hold RPRX as of Q3 2014.

  • Kingdon Capital Management reported no remaining Repros Therapeutics Inc. position as of Q3 2014 after selling out during the quarter.
  • Kingdon Capital Management sold 92,318 Repros Therapeutics Inc. shares in Q3 2014, an estimated $1.6M.
  • Kingdon Capital Management first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 5 quarters.
  • Kingdon Capital Management's Repros Therapeutics Inc. position peaked at $13.2M in Q2 2013.
  • 75 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q3 2014.

Based on Kingdon Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.